Sodium–glucose cotransporter 2 (SGLT2) inhibitors provide metabolic and cardiorenal benefits for patients with type 2 diabetes but are associated with a number of safety issues. Here, we discuss evidence suggesting that indirect activation of the FGF23–1,25-dihydroxyvitamin D–parathyroid hormone axis by SGLT2 inhibition might contribute to adverse effects on bone health.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Trends in osteoporosis and mean bone density among type 2 diabetes patients in the US from 2005 to 2014
Scientific Reports Open Access 12 February 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
DeFronzo, R. A., Norton, L. & Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 13, 11–26 (2017).
Kohan, D. E., Fioretto, P., Tang, W. & List, J. F. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 85, 962–971 (2014).
Bilezikian, J. P. et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J. Clin. Endocrinol. Metab. 101, 44–51 (2016).
Watts, N. B. et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 101, 157–166 (2016).
Blau, J. E. et al. Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight 3, 99123 (2018).
Pitts, R. F. & Alexander, R. S. The renal reabsorptive mechanism for inorganic phosphate in normal and acidotic dogs. Am. J. Physiol. 142, 648–662 (1944).
Acknowledgements
J.E.B. is supported by funding from the Intramural Research Program of the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). S.I.T. acknowledges funding from the NIDDK (grant number P30DK072488).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.E.B. declares no competing interests. S.I.T. is a consultant for Ionis Pharmaceuticals, has research support provided to the University of Maryland School of Medicine by Regeneron Pharmaceuticals and has ownership of stock in Celgene, Amgen and Abbott Laboratories.
Rights and permissions
About this article
Cite this article
Blau, J.E., Taylor, S.I. Adverse effects of SGLT2 inhibitors on bone health. Nat Rev Nephrol 14, 473–474 (2018). https://doi.org/10.1038/s41581-018-0028-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-018-0028-0
This article is cited by
-
Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Osteoporosis International (2023)
-
Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction
Heart Failure Reviews (2022)
-
Trends in osteoporosis and mean bone density among type 2 diabetes patients in the US from 2005 to 2014
Scientific Reports (2021)
-
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Nature Reviews Endocrinology (2020)
-
Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits
Current Osteoporosis Reports (2020)